Dikkat Eksikliği ve Hiperaktivite Bozukluğunda Gıda ve Multivitamin Gibi Takviyelerin Yeri

Polanczyk, G. V., Salum, G. A., Sugaya, L. S., et al. (2015). Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry, 56, 345–365.

Ercan, E. S., et al. (2019) The prevalence of childhood psychopathology in Turkey: a cross-sectional multicenter nationwide study (EPICPAT-T). Nord J Psychiatry, 73(2), 132-140.

Biederman, J. (2005). Attention-deficit/hyperactivity disorder: a selective overview. Biological Psychiatry, 57(11), 1215-20.

Kidd, P. M. (2007). Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. Altern Med Rev, 12(3), 207-27.

Gow, R. V., Hibbeln, J. R. (2014). Omega-3 fatty acid and nutrient deficits in adverse neurodevelopment and childhood behaviors. Child Adolesc Psychiatr Clin N Am, 23(3), 555-90.

Patrick, R. P., Ames, B. N. (2015). Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior. FASEB J, 29(6), 2207-22.

Hibbeln, J. R., Davis, J. M., Steer, C., Emmett, P., Rogers, I., Williams, C., Golding, J. (2007). Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. Lancet, 17;369(9561), 578-85.

Janssen, C. I., Kiliaan, A. J. (2014). Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration. Prog Lipid Res, 53, 1-17.

Gould, J. F., Roberts, R. M., Makrides, M. (2021). The Influence of Omega-3 Long-Chain Polyunsaturated Fatty Acid, Docosahexaenoic Acid, on Child Behavioral Functioning: A Review of Randomized Controlled Trials of DHA Supplementation in Pregnancy, the Neonatal Period and Infancy. Nutrients, 28;13(2), 415.

Gould, J. F., Roberts, R. M., Anderson, P. J., Makrides, M., Sullivan, T. R., Gibson, R. A., McPhee, A. J., Doyle, L. W., Bednarz, J. M., Best, K. P., Opie, G., Travadi, J., Cheong, J. L. Y., Davis, P. G., Sharp, M., Simmer, K., Tan, K., Morris, S., Lui, K., Bolisetty, S., Liley, H., Stack, J., Collins, C. T. (2024). High-Dose Docosahexaenoic Acid in Newborns Born at Less Than 29 Weeks' Gestation and Behavior at Age 5 Years: Follow-Up of a Randomized Clinical Trial. JAMA Pediatr, 1;178(1), 45-54.

Hawkey, E., Nigg, J. T. (2014). Omega-3 fatty acid and ADHD: blood level analysis and meta-analytic extension of supplementation trials. Clin Psychol Rev, 34(6), 496-505.

Bloch, M. H., Qawasmi, A. (2011). Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry, 50(10), 991-1000.

Barragán, E., Breuer, D., Döpfner, M. (2017). Efficacy and Safety of Omega-3/6 Fatty Acids, Methylphenidate, and a Combined Treatment in Children With ADHD. J Atten Disord, 21(5), 433-441.

Anand, P., Sachdeva, A. (2016). Effect of Poly Unsaturated Fatty Acids Administration on Children with Attention Deficit Hyperactivity Disorder: A Randomized Controlled Trial. J Clin Diagn Res, 10(9), OC01-OC05.

Agostoni, C., Nobile, M., Ciappolino, V., Delvecchio, G., Tesei, A., Turolo, S., Crippa, A., Mazzocchi, A., Altamura, C. A., Brambilla, P. (2017). The Role of Omega-3 Fatty Acids in Developmental Psychopathology: A Systematic Review on Early Psychosis, Autism, and ADHD. Int J Mol Sci, 4;18(12), 2608.

Chang, J. P., Su, K. P., Mondelli, V., Pariante, C. M. (2018). Omega-3 Polyunsaturated Fatty Acids in Youths with Attention Deficit Hyperactivity Disorder: a Systematic Review and Meta-Analysis of Clinical Trials and Biological Studies. Neuropsychopharmacology, 43(3), 534-545.

Chang, J. P., Su, K. P., Mondelli, V., Satyanarayanan, S. K., Yang, H. T., Chiang, Y. J., Chen, H. T., Pariante, C. M. (2019). High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels. Transl Psychiatry, 20;9(1), 303.

Gow, R. V., Sumich, A., Vallee-Tourangeau, F., Crawford, M. A., Ghebremeskel, K., Bueno, A. A., Hibbeln, J. R., Taylor, E., Wilson, D. A., Rubia, K. (2013). Omega-3 fatty acids are related to abnormal emotion processing in adolescent boys with attention deficit hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids, 88(6), 419-29.

Bellino, S., Bozzatello, P., Badino, C., Mantelli, E., Rocca, P. (2021). Efficacy of Polyunsaturated Fatty Acids (PUFAs) on Impulsive Behaviours and Aggressiveness in Psychiatric Disorders. Int J Mol Sci, 9;22(2), 620.

Döpfner, M., Dose, C., Breuer, D., Heintz, S., Schiffhauer, S., Banaschewski, T. (2021). Efficacy of Omega-3/Omega-6 Fatty Acids in Preschool Children at Risk of ADHD: A Randomized Placebo-Controlled Trial. J Atten Disord, 25(8), 1096-1106.

Königs, A., Kiliaan, A. (2016). Critical appraisal of omega-3 fatty acids in attention-deficit/hyperactivity disorder treatment. Neuropsychiatric Disease and Treatment 12, 1869–1882.

Chang, J. P., Su, K. P. (2020). Nutritional Neuroscience as Mainstream of Psychiatry: The Evidence- Based Treatment Guidelines for Using Omega-3 Fatty Acids as a New Treatment for Psychiatric Disorders in Children and Adolescents. Clin Psychopharmacol Neurosci, 30;18(4), 469-483.

D'Helft, J., Caccialanza, R., Derbyshire, E., Maes, M. (2022). Relevance of ω-6 GLA Added to ω-3 PUFAs Supplements for ADHD: A Narrative Review. Nutrients, 10;14(16), 3273.

Cao, J., Schwichtenberg, K. A., Hanson, N. Q., & Tsai, M. Y. (2006). Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids. Clinical Chemistry, 52, 2265-2272.

Stanley, J. A., Kipp, H., Greisenegger, E., MacMaster, F. P., Panchalingam, K., Pettegrew, J. W., Keshavan, M. S., Bukstein, O. G. (2006). Regionally specific alterations in membrane phospholipids in children with ADHD: An in vivo 31P spectroscopy study. Psychiatry Res, 1;148(2-3), 217-21.

Bruton, A., Nauman, J., Hanes, D., Gard, M., Senders, A. (2021). Phosphatidylserine for the Treatment of Pediatric Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. J Altern Complement Med, 27(4), 312-322.

Hirayama, S., Masuday, R. R. (2006). Effect of phosphatidylserine administration on symptoms of attention-deficit/hyperactivity disorder in children. AgroFOOD Ind hi-tech, 17, 32–36.

Vaisman, N., Kaysar, N., Zaruk-Adasha, Y., et al. (2008). Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: Effect of dietary n-3 fatty acids containing phospholipids. Am J Clin Nutr, 87, 1170–1180.

Manor, I., Magen, A., Keidar, D., et al. (2012). The effect of phosphatidylserine containing Omega-3 fatty-acids on attention deficit hyperactivity disorder symptoms in children: A double-blind placebo-controlled trial, followed by an open label extension. Eur Psychiatry, 27, 335–342.

Hirayama, S., Terasawa, K., Rabeler, R., et al. (2014). The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: A rando mised, double-blind, placebo-controlled clinical trial. J Hum Nutr Diet, 27, 284–291.

Manor, I., Magen, A., Keidar, D., et al. (2013). Safety of phosphatidylserine containing Omega-3 fatty acids in ADHD children: A double-blind placebo-controlled trial followed by an open-label extension. Eur Psychiatry, 28, 386–391.

Rheims, S., Herbillon, V., Gaillard, S., Mercier, C., Villeuve, N., Villéga, F., Cances, C., Castelnau, P., Napuri, S., de Saint-Martin, A., Auvin, S., Nguyen The Tich, S., Berquin, P., de Bellecize, J., Milh, M., Roy, P., Arzimanoglou, A., Bodennec, J., Bezin, L., Kassai, B.; investigators of the AGPI study group. (2024). Phosphatidylserine enriched with polyunsaturated n-3 fatty acid supplementation for attention-deficit hyperactivity disorder in children and adolescents with epilepsy: A randomized placebo-controlled trial. Epilepsia Open, 9(2), 582-591.

Secades, J. J. (2019). Citicoline in the Treatment of Cognitive Impairment. J Neurol Exp Neurosci, 5(1), 14-26.

Al Mosawi AJ. (2019). The Use of Citicoline in Pediatric Neurology and Pediatric Psychiatry. Austin Pediatr, 6(1), 1071.

Shamansurov, S. S., Saidazizova, S. K., Tulyaganova, N. M., Usmanova, P. T., & Nazarova, S. O. (2023). Dynamics of clinical and neurological parameters and role of citicoline during therapeutic interventions in children with stroke. Future Neurology, 18(1).

Salamah, A., Mehrez, M., Faheem, A. et al. (2021). Efficacy of Citicoline as a Neuroprotector in children with post cardiac arrest: a randomized controlled clinical trial. Eur J Pediatr 180, 1249–1255.

McGlade, E., Locatelli, A., Hardy, J., Kamiya, T., Morita, M., Morishita, K., Sugimura, Y., Yurgelun-Todd, D. (2012). Improved Attentional Performance Following Citicoline Administration in Healthy Adult Women. Food and Nutrition Sciences, 3, 769-773.

McGlade, E., Agoston, A. M., DiMuzio, J., Kizaki, M., Nakazaki, E., Kamiya, T., Yurgelun-Todd, D. (2019). The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males. J Atten Disord, 23, 121-134.

Sarris, J., Ravindran, A., Yatham, L. N., Marx, W., Rucklidge, J. J,, McIntyre, R. S., Akhondzadeh, S., Benedetti, F., Caneo, C., Cramer, H., Cribb, L., de Manincor, M., Dean, O., Deslandes, A. C., Freeman, M. P., Gangadhar, B., Harvey, B. H., Kasper, S., Lake, J., Lopresti, A., Lu, L., Metri, N. J., Mischoulon, D., Ng, C. H., Nishi, D., Rahimi, R., Seedat, S., Sinclair, J., Su, K. P., Zhang, Z. J., Berk, M. (2022). Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J Biol Psychiatry, 23(6), 424-455.

Rucklidge, J. J., Frampton, C. M., Gorman, B., Boggis, A. (2014). Vitamin-mineral treatment of attention-deficit hyperactivity disorder in adults: Double-blind randomised placebo-controlled trial. Br. J. Psychiatry, 204, 306–315.

Sinn, N., Bryan, J. (2007). Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J. Dev. Behav. Pediatr, 28, 82–91.

Rucklidge, J. J., Eggleston, M. J., Johnstone, J. M., Darling, K., Frampton, C. M. (2018). Vitamin-mineral treatment improves aggression and emotional regulation in children with ADHD: A fully blinded, randomized, placebo-controlled trial. J. Child Psychol. Psychiatry, 59, 232–246.

Johnstone, J. M., Hughes, A., Goldenberg, J. Z., Romijn, A. R., Rucklidge, J. J. (2020). Multinutrients for the treatment of psychiatric symptoms in clinical samples: a systematic review and meta-analysis of randomized controlled trials. Nutrients, 12(11), 3394.

Gan, J., Galer, P., Ma, D., Chen, C., Xiong, T. (2019). The effect of vitamin D supplementation on attention-deficit/hyper activity disorder: a systematic review and meta-analysis of randomized controlled trials. J Child Adolesc Psychopharmacology, 29(9), 670–687.

Akhondzadeh, S., Mohammadi, M.-R., Khademi, M. (2004). Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371]. BMC Psychiatry, 4 (1), 9.

Huss, M., Völp, A., Stauss-Grabo, M. (2010). Supplementation of polyunsaturated fatty acids, magnesium and zinc in children seeking medical advice for attention-deficit/ hyperactivity problems-an observational cohort study. Lipids Health Dis, 9 (1), 105.

Arnold, L. E., Disilvestro, R. A., Bozzolo, D., Bozzolo, H., Crowl, L., Fernandez, S., Ramadan, Y., Thompson, S., Mo, X., Abdel Rasoul, M., et al. (2011). Zinc for attention-deficit/hyperactiv ity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine. J Child Adolesc Psychopharmacology, 21(1), 1–19.

Noorazar, S. G., Malek, A., Aghaei, S. M., Yasamineh, N., Kalejahi, P. (2020). The efficacy of zinc augmentation in children with attention deficit hyperactivity disorder under treatment with methylphenidate: a randomized controlled trial. Asian J Psychiatr, 48.

Salehi, B., Imani, R., Mohammadi, M. R., Fallah, J., Mohammadi, M., Ghanizadeh, A., et al. (2010). Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial. Prog Neuro psychopharmacol Biol Psychiatry, 34, 76-80.

Shakibaei, F., Radmanesh, M., Salari, E., Mahaki, B. (2015). Ginkgo biloba in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. A randomized, placebo-controlled, trial. Complement Ther Clin Pract, 21(2), 61–67.

Zhou, P., Yu, X., Song, T., Hou, X. (2024). Safety and efficacy of antioxidant therapy in children and adolescents with attention deficit hyperactivity disorder: A systematic review and network meta-analysis. PLoS One, 28;19(3).

Polanczyk, G. V., Salum, G. A., Sugaya, L. S., et al. (2015). Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry, 56, 345–365.

Ercan, E. S., et al. (2019) The prevalence of childhood psychopathology in Turkey: a cross-sectional multicenter nationwide study (EPICPAT-T). Nord J Psychiatry, 73(2), 132-140.

Biederman, J. (2005). Attention-deficit/hyperactivity disorder: a selective overview. Biological Psychiatry, 57(11), 1215-20.

Kidd, P. M. (2007). Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. Altern Med Rev, 12(3), 207-27.

Gow, R. V., Hibbeln, J. R. (2014). Omega-3 fatty acid and nutrient deficits in adverse neurodevelopment and childhood behaviors. Child Adolesc Psychiatr Clin N Am, 23(3), 555-90.

Patrick, R. P., Ames, B. N. (2015). Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior. FASEB J, 29(6), 2207-22.

Hibbeln, J. R., Davis, J. M., Steer, C., Emmett, P., Rogers, I., Williams, C., Golding, J. (2007). Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. Lancet, 17;369(9561), 578-85.

Janssen, C. I., Kiliaan, A. J. (2014). Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration. Prog Lipid Res, 53, 1-17.

Gould, J. F., Roberts, R. M., Makrides, M. (2021). The Influence of Omega-3 Long-Chain Polyunsaturated Fatty Acid, Docosahexaenoic Acid, on Child Behavioral Functioning: A Review of Randomized Controlled Trials of DHA Supplementation in Pregnancy, the Neonatal Period and Infancy. Nutrients, 28;13(2), 415.

Gould, J. F., Roberts, R. M., Anderson, P. J., Makrides, M., Sullivan, T. R., Gibson, R. A., McPhee, A. J., Doyle, L. W., Bednarz, J. M., Best, K. P., Opie, G., Travadi, J., Cheong, J. L. Y., Davis, P. G., Sharp, M., Simmer, K., Tan, K., Morris, S., Lui, K., Bolisetty, S., Liley, H., Stack, J., Collins, C. T. (2024). High-Dose Docosahexaenoic Acid in Newborns Born at Less Than 29 Weeks' Gestation and Behavior at Age 5 Years: Follow-Up of a Randomized Clinical Trial. JAMA Pediatr, 1;178(1), 45-54.

Hawkey, E., Nigg, J. T. (2014). Omega-3 fatty acid and ADHD: blood level analysis and meta-analytic extension of supplementation trials. Clin Psychol Rev, 34(6), 496-505.

Bloch, M. H., Qawasmi, A. (2011). Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry, 50(10), 991-1000.

Barragán, E., Breuer, D., Döpfner, M. (2017). Efficacy and Safety of Omega-3/6 Fatty Acids, Methylphenidate, and a Combined Treatment in Children With ADHD. J Atten Disord, 21(5), 433-441.

Anand, P., Sachdeva, A. (2016). Effect of Poly Unsaturated Fatty Acids Administration on Children with Attention Deficit Hyperactivity Disorder: A Randomized Controlled Trial. J Clin Diagn Res, 10(9), OC01-OC05.

Agostoni, C., Nobile, M., Ciappolino, V., Delvecchio, G., Tesei, A., Turolo, S., Crippa, A., Mazzocchi, A., Altamura, C. A., Brambilla, P. (2017). The Role of Omega-3 Fatty Acids in Developmental Psychopathology: A Systematic Review on Early Psychosis, Autism, and ADHD. Int J Mol Sci, 4;18(12), 2608.

Chang, J. P., Su, K. P., Mondelli, V., Pariante, C. M. (2018). Omega-3 Polyunsaturated Fatty Acids in Youths with Attention Deficit Hyperactivity Disorder: a Systematic Review and Meta-Analysis of Clinical Trials and Biological Studies. Neuropsychopharmacology, 43(3), 534-545.

Chang, J. P., Su, K. P., Mondelli, V., Satyanarayanan, S. K., Yang, H. T., Chiang, Y. J., Chen, H. T., Pariante, C. M. (2019). High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels. Transl Psychiatry, 20;9(1), 303.

Gow, R. V., Sumich, A., Vallee-Tourangeau, F., Crawford, M. A., Ghebremeskel, K., Bueno, A. A., Hibbeln, J. R., Taylor, E., Wilson, D. A., Rubia, K. (2013). Omega-3 fatty acids are related to abnormal emotion processing in adolescent boys with attention deficit hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids, 88(6), 419-29.

Bellino, S., Bozzatello, P., Badino, C., Mantelli, E., Rocca, P. (2021). Efficacy of Polyunsaturated Fatty Acids (PUFAs) on Impulsive Behaviours and Aggressiveness in Psychiatric Disorders. Int J Mol Sci, 9;22(2), 620.

Döpfner, M., Dose, C., Breuer, D., Heintz, S., Schiffhauer, S., Banaschewski, T. (2021). Efficacy of Omega-3/Omega-6 Fatty Acids in Preschool Children at Risk of ADHD: A Randomized Placebo-Controlled Trial. J Atten Disord, 25(8), 1096-1106.

Königs, A., Kiliaan, A. (2016). Critical appraisal of omega-3 fatty acids in attention-deficit/hyperactivity disorder treatment. Neuropsychiatric Disease and Treatment 12, 1869–1882.

Chang, J. P., Su, K. P. (2020). Nutritional Neuroscience as Mainstream of Psychiatry: The Evidence- Based Treatment Guidelines for Using Omega-3 Fatty Acids as a New Treatment for Psychiatric Disorders in Children and Adolescents. Clin Psychopharmacol Neurosci, 30;18(4), 469-483.

D'Helft, J., Caccialanza, R., Derbyshire, E., Maes, M. (2022). Relevance of ω-6 GLA Added to ω-3 PUFAs Supplements for ADHD: A Narrative Review. Nutrients, 10;14(16), 3273.

Cao, J., Schwichtenberg, K. A., Hanson, N. Q., & Tsai, M. Y. (2006). Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids. Clinical Chemistry, 52, 2265-2272.

Stanley, J. A., Kipp, H., Greisenegger, E., MacMaster, F. P., Panchalingam, K., Pettegrew, J. W., Keshavan, M. S., Bukstein, O. G. (2006). Regionally specific alterations in membrane phospholipids in children with ADHD: An in vivo 31P spectroscopy study. Psychiatry Res, 1;148(2-3), 217-21.

Bruton, A., Nauman, J., Hanes, D., Gard, M., Senders, A. (2021). Phosphatidylserine for the Treatment of Pediatric Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. J Altern Complement Med, 27(4), 312-322.

Hirayama, S., Masuday, R. R. (2006). Effect of phosphatidylserine administration on symptoms of attention-deficit/hyperactivity disorder in children. AgroFOOD Ind hi-tech, 17, 32–36.

Vaisman, N., Kaysar, N., Zaruk-Adasha, Y., et al. (2008). Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: Effect of dietary n-3 fatty acids containing phospholipids. Am J Clin Nutr, 87, 1170–1180.

Manor, I., Magen, A., Keidar, D., et al. (2012). The effect of phosphatidylserine containing Omega-3 fatty-acids on attention deficit hyperactivity disorder symptoms in children: A double-blind placebo-controlled trial, followed by an open label extension. Eur Psychiatry, 27, 335–342.

Hirayama, S., Terasawa, K., Rabeler, R., et al. (2014). The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: A rando mised, double-blind, placebo-controlled clinical trial. J Hum Nutr Diet, 27, 284–291.

Manor, I., Magen, A., Keidar, D., et al. (2013). Safety of phosphatidylserine containing Omega-3 fatty acids in ADHD children: A double-blind placebo-controlled trial followed by an open-label extension. Eur Psychiatry, 28, 386–391.

Rheims, S., Herbillon, V., Gaillard, S., Mercier, C., Villeuve, N., Villéga, F., Cances, C., Castelnau, P., Napuri, S., de Saint-Martin, A., Auvin, S., Nguyen The Tich, S., Berquin, P., de Bellecize, J., Milh, M., Roy, P., Arzimanoglou, A., Bodennec, J., Bezin, L., Kassai, B.; investigators of the AGPI study group. (2024). Phosphatidylserine enriched with polyunsaturated n-3 fatty acid supplementation for attention-deficit hyperactivity disorder in children and adolescents with epilepsy: A randomized placebo-controlled trial. Epilepsia Open, 9(2), 582-591.

Secades, J. J. (2019). Citicoline in the Treatment of Cognitive Impairment. J Neurol Exp Neurosci, 5(1), 14-26.

Al Mosawi AJ. (2019). The Use of Citicoline in Pediatric Neurology and Pediatric Psychiatry. Austin Pediatr, 6(1), 1071.

Shamansurov, S. S., Saidazizova, S. K., Tulyaganova, N. M., Usmanova, P. T., & Nazarova, S. O. (2023). Dynamics of clinical and neurological parameters and role of citicoline during therapeutic interventions in children with stroke. Future Neurology, 18(1).

Salamah, A., Mehrez, M., Faheem, A. et al. (2021). Efficacy of Citicoline as a Neuroprotector in children with post cardiac arrest: a randomized controlled clinical trial. Eur J Pediatr 180, 1249–1255.

McGlade, E., Locatelli, A., Hardy, J., Kamiya, T., Morita, M., Morishita, K., Sugimura, Y., Yurgelun-Todd, D. (2012). Improved Attentional Performance Following Citicoline Administration in Healthy Adult Women. Food and Nutrition Sciences, 3, 769-773.

McGlade, E., Agoston, A. M., DiMuzio, J., Kizaki, M., Nakazaki, E., Kamiya, T., Yurgelun-Todd, D. (2019). The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males. J Atten Disord, 23, 121-134.

Sarris, J., Ravindran, A., Yatham, L. N., Marx, W., Rucklidge, J. J,, McIntyre, R. S., Akhondzadeh, S., Benedetti, F., Caneo, C., Cramer, H., Cribb, L., de Manincor, M., Dean, O., Deslandes, A. C., Freeman, M. P., Gangadhar, B., Harvey, B. H., Kasper, S., Lake, J., Lopresti, A., Lu, L., Metri, N. J., Mischoulon, D., Ng, C. H., Nishi, D., Rahimi, R., Seedat, S., Sinclair, J., Su, K. P., Zhang, Z. J., Berk, M. (2022). Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J Biol Psychiatry, 23(6), 424-455.

Rucklidge, J. J., Frampton, C. M., Gorman, B., Boggis, A. (2014). Vitamin-mineral treatment of attention-deficit hyperactivity disorder in adults: Double-blind randomised placebo-controlled trial. Br. J. Psychiatry, 204, 306–315.

Sinn, N., Bryan, J. (2007). Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J. Dev. Behav. Pediatr, 28, 82–91.

Rucklidge, J. J., Eggleston, M. J., Johnstone, J. M., Darling, K., Frampton, C. M. (2018). Vitamin-mineral treatment improves aggression and emotional regulation in children with ADHD: A fully blinded, randomized, placebo-controlled trial. J. Child Psychol. Psychiatry, 59, 232–246.

Johnstone, J. M., Hughes, A., Goldenberg, J. Z., Romijn, A. R., Rucklidge, J. J. (2020). Multinutrients for the treatment of psychiatric symptoms in clinical samples: a systematic review and meta-analysis of randomized controlled trials. Nutrients, 12(11), 3394.

Gan, J., Galer, P., Ma, D., Chen, C., Xiong, T. (2019). The effect of vitamin D supplementation on attention-deficit/hyper activity disorder: a systematic review and meta-analysis of randomized controlled trials. J Child Adolesc Psychopharmacology, 29(9), 670–687.

Akhondzadeh, S., Mohammadi, M.-R., Khademi, M. (2004). Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371]. BMC Psychiatry, 4 (1), 9.

Huss, M., Völp, A., Stauss-Grabo, M. (2010). Supplementation of polyunsaturated fatty acids, magnesium and zinc in children seeking medical advice for attention-deficit/ hyperactivity problems-an observational cohort study. Lipids Health Dis, 9 (1), 105.

Arnold, L. E., Disilvestro, R. A., Bozzolo, D., Bozzolo, H., Crowl, L., Fernandez, S., Ramadan, Y., Thompson, S., Mo, X., Abdel Rasoul, M., et al. (2011). Zinc for attention-deficit/hyperactiv ity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine. J Child Adolesc Psychopharmacology, 21(1), 1–19.

Noorazar, S. G., Malek, A., Aghaei, S. M., Yasamineh, N., Kalejahi, P. (2020). The efficacy of zinc augmentation in children with attention deficit hyperactivity disorder under treatment with methylphenidate: a randomized controlled trial. Asian J Psychiatr, 48.

Salehi, B., Imani, R., Mohammadi, M. R., Fallah, J., Mohammadi, M., Ghanizadeh, A., et al. (2010). Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial. Prog Neuro psychopharmacol Biol Psychiatry, 34, 76-80.

Shakibaei, F., Radmanesh, M., Salari, E., Mahaki, B. (2015). Ginkgo biloba in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. A randomized, placebo-controlled, trial. Complement Ther Clin Pract, 21(2), 61–67.

Zhou, P., Yu, X., Song, T., Hou, X. (2024). Safety and efficacy of antioxidant therapy in children and adolescents with attention deficit hyperactivity disorder: A systematic review and network meta-analysis. PLoS One, 28;19(3).